Greenberg Traurig, Ropes & Gray and Cantor Colburn have all announced high-profile hires in recent weeks, while biologics developer MiMedx has appointed a new chief compliance officer.

⇒ Brian Rubenstein is joining Greenberg Traurig in Philadelphia after 13 years at Teva Pharmaceuticals, where he most recently served as senior director and associate general counsel, the firm said on 16 July.

Rubenstein focuses his practice on product liability, multidistrict and mass tort litigation as well as US Federal Drug Administration and Federal Trade Commission compliance issues.

In his former role he was responsible for Teva’s portfolio of commercial disputes, including patent and product liability matters, and managed the company’s involvement in the US Supreme Court’s 2011 landmark decision in Pliva v Mensing, which held that generics cannot be sued under state law for failing to warn customers about associated product risks.

The ruling “had wide-ranging ramifications in the defense of mass tort product liability litigations within the generic pharmaceutical industry,” Rubenstein told PLN. “But even post-Pliva, as plaintiffs’ lawyers try to craft arguments to get around Pliva, we continue to enhance our other defences.”

Before joining Teva, he worked as a commercial litigation associate in New York, and served as a judicial clerk in the US Court of Appeals for the Seventh Circuit.

“We are thrilled to have Brian join us,” Curtis Toll, managing shareholder of Greenberg Traurig’s Philadelphia office said in a statement, praising Rubenstein’s “deep knowledge of the inner workings of pharmaceutical companies” and “corporate perspective” from his time at Teva.

“With some sizable wins and great opportunities under my belt, I was looking at how I could grow further and become even stronger as an attorney,” Rubenstein said. “Greenberg Traurig was the perfect fit.”

⇒ Ropes & Gray announced that it had hired life sciences IP litigation specialist Charlotte Jacobsen as partner in its New York office on 17 July.

Jacobsen’s experience encompasses complex patent disputes concerning biotechnology, pharmaceuticals, and chemicals, with an emphasis on litigation under the Hatch-Waxman Act. She also counsels clients on Biologics Price Competition and Innovation Act matters.

Having begun her career as a pupil barrister at 8 New Square in London, Jacobsen went on to work as an associate at Milbank Tweed Hadley & McCloy in the city before joining US IP boutique Fitzpatrick Cella Harper & Scinto, where she was made a partner in 2014.

During her time at Fitzpatrick Cella, Jacobsen successfully represented pharmaceutical manufacturer Novartis in several matters, including defending it against a recent inter partes review brought by Par Pharmaceuticals before the US Patent Trial and Appeal Board.

“She’s the advisor that any leading life sciences or biopharmaceutical company would want to consult,” Ropes & Gray’s global IP litigation head said, praising her “winning record handling high-stakes litigation.”

“I am honoured to join Ropes & Gray’s life sciences practice,” Jacobsen added.

⇒ US law firm Cantor Colburn announced on 16 July that it had added Locke Lord’s life sciences co-chair Bryan Zerhusen to its Hartford, Connecticut office.

Zerhusen’s practice focuses on domestic and foreign patent preparation, prosecution and counselling for innovators in the chemical and life science industries.

He began his career as a patent attorney at McCarter & English in 2003, becoming partner in 2012 before joining Locke Lord in 2014.

Bryan is well-known for being a leader with a ready grasp of complex technologies and for having a track record of outstanding client service,” Cantor Colburn co-managing partner Michael Cantor said in a statement.

Zerhusen said Cantor Colburn was a “natural fit” for him, praising its “robust” support systems for patent prosecution.

⇒ Biologics developer MiMedx has appointed Mark Graves as chief compliance officer, the company said on 18 July.

Graves will be responsible for direction and oversight of the company’s compliance programme, including regulatory and risk management, sales operations and financial reporting.

He has over 20 years of experience in the pharmaceutical and biotech industry, most recently as US leader for global patient experience and value function in the neurology division of biopharmaceutical company UCB. From 2011 to 2015, Graves served as the company’s deputy compliance officer.

"Mark has a strong background in driving compliance strategy, risk awareness, training, and crafting effective policy,” David Coles, MiMedx interim CEO said in a statement. “We are pleased to welcome him to our organisation."